Literature DB >> 30357465

[Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].

Gregor Kastl1.   

Abstract

Under a combination therapy with cobimetinib/vemurafenib for the treatment of BRAF-V600 positive metastatic melanoma, symptomatic or asymptomatic bilateral serous retinopathy can occur, which is reversible after dose reduction or treatment discontinuation. In the case presented the progress of bilateral serous retinopathy was documented by optical coherence tomography (OCT). After therapy discontinuation, subfoveal fluid levels varied until remission was reached six months later.

Entities:  

Keywords:  BRAF-V600 mutation; Cobimetinib; Metastatic melanoma; Serous retinopathy; Vemurafenib

Mesh：

Substances：

Year:  2019        PMID： 30357465     DOI： 10.1007/s00347-018-0803-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  7 in total

1.  [Multifocal serous chorioretinopathy secondary to the use of MEK inhibitors: Illustration and example of management through two case reports].

Authors:  A Coutu; F Farguette; G Jeannin; F Chiambaretta
Journal:  J Fr Ophtalmol       Date:  2015-12-30       Impact factor: 0.818

Review 2.  The retinal pigment epithelium in visual function.

Authors:  Olaf Strauss
Journal:  Physiol Rev       Date:  2005-07       Impact factor: 37.312

3.  MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells.

Authors:  Qin Jiang; Cong Cao; Shan Lu; Rebecca Kivlin; Brittany Wallin; Wenming Chu; Zhigang Bi; Xinru Wang; Yinsheng Wan
Journal:  Int J Mol Med       Date:  2009-06       Impact factor: 4.101

Review 4.  MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.

Authors:  Antonio M Grimaldi; Ester Simeone; Lucia Festino; Vito Vanella; Martina Strudel; Paolo A Ascierto
Journal:  Am J Clin Dermatol       Date:  2017-12       Impact factor: 7.403

Review 5.  Blood-retinal barrier.

Authors:  José Cunha-Vaz; Rui Bernardes; Conceição Lobo
Journal:  Eur J Ophthalmol       Date:  2011       Impact factor: 2.597

6.  Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.

Authors:  Luis de la Cruz-Merino; Lorenza Di Guardo; Jean-Jacques Grob; Alfredo Venosa; James Larkin; Grant A McArthur; Antoni Ribas; Paolo A Ascierto; Jeffrey T R Evans; Antonio Gomez-Escobar; Giulio Barteselli; Susan Eng; Jessie J Hsu; Anne Uyei; Brigitte Dréno
Journal:  J Transl Med       Date:  2017-06-24       Impact factor: 5.531

7.  Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.

Authors:  Elon H C van Dijk; Danique E M Duits; Mieke Versluis; Gregrorius P M Luyten; Arthur A B Bergen; Ellen W Kapiteijn; Mark J de Lange; Camiel J F Boon; Pieter A van der Velden
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.